Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Certican-reduced Neoral versus MMF-standard Neoral in de novo heart transplant recipients
2005-003413-32Phase 3Completed
- Sponsor
- Novartis
- Start
- Dec 2005
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of everolimus, cyclosporine and mycophenolate mofetil in Cardiac Rejection (3 arms), sponsored by Novartis. Primary endpoints: Primary efficacy failure at 12 months and Composite efficacy failure. Started Dec 2005; status: completed.
02
Drugs
everolimuscyclosporinemycophenolate mofetil
03
Conditions
Cardiac Rejection
Beyond the preview
Go deeper on 2005-003413-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-003413-32.